NGAL test Distribution Agreement with Wiener Group

By On 1. June 2012 · 8 Comments · In BioPorto

Today BioPorto announced that they have entered into a Distribution Agreement with Wiener Group for an NGAL assay. The Agreement includes sale, marketing and registration process in Latin America

Wiener Group is Argentine based, working primarily in Argentina and Brazil (and other latin american countries) – info about the company can be found below..  The Wiener Group is – like Instrumentation Lab – a producer of analyzers. However – contrary to IL, Wiener Group has decided to use a homogenous Test on their analyzers (rather than develop their own heterogenous) , and are amongst the first machine producers to adopt the turbidemetry testformat for the NGAL test. The Wiener group already market other Turbitests…

I expect to see more such Agreements with local/regional players who have their own line of analyzers. In fact – I think we will se a steadily rising numbers of such Agreements in the near to medium term future, basically beacuse other the small/medium-sized manufacturers are aware of the risk of being left out… BioPorto will not have the capacity to validate all types of analyzers – so in order to have a leading edge they (the manufacturers) will have to undertake this themselves.

Now I know many of you still frown at hospitals in Brazil, Latin America and in the other Bric-countries such as China and India. But – please bear in mind – that the economy and living standard of the middle class in these countries are rising steeply.

Why is that – well those of us who have been to Africa lately, have witnessed that the phone-net in Africa is working smoothly, very smoothly in contrast to the infrastructure. The Africans simply bypassed the old copperbased systems and when straigth to state-of-the-art technology. The same thing is happening right now with the hospital-sector in the Bric Countries. Not being bound by old routines – og old machinery – this sector will be technology-driven – far faster thanEurope/US – where the financial crisis is still very much menu of the day..

Actually – I predict that The NGAL test will be integrated in routine diagnostics in China, India, Brazil and other advancing countries far more rapidly than in Europe. Indeed – this might be exactly the kind of breakthrough that companies like BioPorto can thrive on.

However – and this is also of paramount importance – BioPorto needs to sign Agreements with the Global Players as well, only they can PUSH the new technology in the still principal markets, and only they can initialize the intense marketing that is still needed. This Agreement (with Wiener Group) is NOT the Agreement that BioPorto has promised in Q2 – but it is significant in as much as it outlines the future for the NGAL test

http://www.wiener-lab.com.ar/wienerw/en/index.vsp

http://www.linkedin.com/company/wiener-lab-group

http://www.wiener-lab.com.ar/wienerw/en/instrumentos_open.vsp?nid=27369

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Related posts:

  1. The first (and so far only) NGAL license agreement. In march 2011, Bioporto signed the first non-exclusive license agreement...
  2. NGAL-test – a marker for anemia ? The NGAL- test has hiherto primarily been connected with measurement...
  3. Will they ever bring the NGAL test to the market? In November 2010, a productmanager from Beckman Coulter Diagnostics said:...
  4. 2014 – a threat for Bioporto, the NGAL-patent or the NGAL-test ?? Uncertainty about consequences of the recent decision by  the European...
Tagged with: • • •
 

8 Responses to NGAL test Distribution Agreement with Wiener Group

  1. Medicoinvestor says:
    6. June 2012 at 18:56

    Det officielle svar på om det var "den lovede aftale" i Q2.

    Hej X.

    "Aftalen med Wiener Lab Group om registrering og salg af NGAL tests til Wiener Labs instrumenter er den første aftale med en instrumentleverandør. Aftalen er gældende regionalt for hele Latin Amerika, herunder i Brasilien, der udgør et af vores fokusområder. BioPorto er endvidere langt i drøftelserne om etablering af samarbejde med flere af de mest betydningsfulde globale aktører, og resultaterne heraf vil løbende blive offentliggjort."

    Reply
  2. Jacob says:
    5. June 2012 at 06:22

    Lige 3 ting…jeg kom til at tænke på. 1.En aftale med Siemens gør så at de hurtigt får solgt flere test ? Aftalen alene skaber jo ikke salg… 2. Hvordan kan de lige sige at aftalen kommer hjem senest juni. Hvorfor er den så ikke på plads……… ved godt vi stadig er i juni. De har vel ikke lavet en aftale om at de forhandler frem til 30 juni, og så indgår de aftalen med det resultat de pr. 3006 har forhandlet sig frem til…..3. Hvis aftalen med siemens giver kurs 10+, er kurs 50 så stadig realistisk indenfor et par år ? Ved godt du hader at gætte 🙂

    Reply
    • Medicoinvestor says:
      6. June 2012 at 06:33

      (Svar fra Stengaard. Slettet af tekniske årsager. Nu genindsat.)

      Hej jacob,
      Først og fremmest – der er ingen (udover BioP og deres samtalepartner) der ved om det er Siemens – eller Roche – eller Orthro – eller ???????
      Traditionelt disponerer de store diagnostiske firmaer i 4. kvartal – hvilket så nok også passer med at BioP har mulighed for at lave en CE-mærkning der garantere holdbarhed af produktet i 24 måneder… Men for at svare på dit spørgsmål – nej i sig selv giver en aftale ikke umiddelbart mere salg. Men man kan roligt sige at signalværdien i en aftale med en af verdens største diagnostiske firmaer vil være meget betydningsfuld – det er (hvis det sker) at betragte som et ridderslag der siger "BioPorto har udviklet den bedtse test på markedet og vi vil sørge for at den udbredes" Omkring tidsforløb Normalt etablerer man aftaler ved at man udveksler term sheets, der beskriver forhandlingerne, og stiller rammer op for tidsforløbet for de enkelte punkter, f.eks. så-og-så-lang-tid til validering, så-og-så-lang-tid tiljuridisk afklaring, så-og-så-lang-tid til geografiske afgrænsning, prisstruktur, aftageform, markedsføringsindsats .o.s.v. o.s.v.
      Der er ingen der kan give dig et eksakt bud på om kurs 50 er realistisk inden for et par år.. –

      Reply
  3. Chat transcript from the Wiener Group. (In danish) | MedicoInvestor says:
    4. June 2012 at 10:50

    […] NGAL test Distribution Agreement with Wiener Group […]

    Reply
  4. Jacob says:
    3. June 2012 at 13:27

    Hej Drue hvordan kan du vide at det ikke er den aftale der skulle få kursen til at stige til det kurs 10 og hvad er der bedre ved den aftale vi så venter på og som skulle komme senest i juni ??

    Reply
    • Medicoinvestor says:
      3. June 2012 at 14:02

      "den aftale der skulle få kursen til at stige til kurs 10"

      Altså, nu er der jo ingen som har lovet at den ville stige til kurs 10. Men lad gå, det vil den jo formentlig nok, og gerne lidt mere også.

      Altså hvis du læser den her aftale igennem, så er det en aftale om levering af NGAL til en spiller på det Sydamerikanske marked, som køber NGAL til at smide i deres egen test. En test som for øvrigt lige skal udvikles først.

      Den aftale som vi venter på er med en producent af et globalt benyttet mærke af testapperater, som f.eks Roche, Siemens eller Abbott.

      Global/Lokal…. its one hell of a difference.

      Reply
  5. SteinHof says:
    1. June 2012 at 17:54

    I guess we will see many "private label" products containing NGAL reagents from BioPorto in the future.

    Reply
  6. Medicoinvestor says:
    1. June 2012 at 17:48

    What's also interesting is that the agreement is only on NGAL test reagents, and that Wiener Group is developing their own assay.
    In my oppinion that indicates that other that the "Bioporto hangarounds" belive in the "marvel of NGAL"…

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.